STAND. COM. REP. NO. 349-06
Honolulu, Hawaii
, 2006
RE: H.B. No. 1869
H.D. 1
Honorable Calvin K.Y. Say
Speaker, House of Representatives
Twenty-Third State Legislature
Regular Session of 2006
State of Hawaii
Sir:
Your Committees on Consumer Protection & Commerce and Health, to which was referred H.B. No. 1869 entitled:
"A BILL FOR AN ACT RELATING TO ADVERTISING BY DRUG MANUFACTURERS AND DISCLOSURE OF CLINICAL TRIALS,"
beg leave to report as follows:
The purpose of this bill is to increase prescription drug safety and the availability of accurate information on prescription drugs by:
(1) Mandating that prescription drug clinical trial results be posted on the Internet;
(2) Requiring prescription drug ads to meet federal standards;
(3) Requiring drug manufacturers to pay fees to the Department of Health;
(4) Establishing penalties for noncompliance; and
(5) Using fees to fund a public education initiative to inform consumers about clinical trials and drug safety information.
ILWU Local 142, the Consumers Union, and National Legislative Association on Prescription Drug Prices submitted testimony in support of this bill. Pharmaceutical Research and Manufacturers of America testimony opposed this measure.
Your Committees have amended this bill by:
(1) Changing the effective date to July 1, 2050, to encourage further discussion; and
(2) Making technical, nonsubstantive amendments for clarity, consistency, and style.
As affirmed by the records of votes of the members of your Committees on Consumer Protection & Commerce and Health that are attached to this report, your Committees are in accord with the intent and purpose of H.B. No. 1869, as amended herein, and recommend that it pass Second Reading in the form attached hereto as H.B. No. 1869, H.D. 1, and be referred to the Committee on Finance.
Respectfully submitted on behalf of the members of the Committees on Consumer Protection & Commerce and Health,
|
____________________________ DENNIS A. ARAKAKI, Chair |
____________________________ ROBERT N. HERKES, Chair |
|